Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
CNS Drugs is Scopus-indexed (Q1, CiteScore 13.7), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Adis.
Checked against the index lists dated .
ISSN 1172-7047Verify ISSN ↗1179-1934Verify ISSN ↗
Publisher: Adis
Cost to publish: About US$5,090 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Psychiatry and Mental Health | 20 / 580 | 96th | Q1 |
| Neurology (clinical) | 15 / 403 | 96th | Q1 |
| Pharmacology (medical) | 11 / 278 | 96th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1994–present, best quartile Q1, CiteScore 13.7.
CNS Drugs is Q1 in Psychiatry and Mental Health (rank 20 of 580), Q1 in Neurology (clinical) (rank 15 of 403) and Q1 in Pharmacology (medical) (rank 11 of 278), by CiteScore 2025.
CNS Drugs is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 13.7, which places it in quartile Q1 at the 96th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 2.161, quartile Q1, with an H-index of 140.
The publisher lists an article processing charge of about US$5,090 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
CNS Drugs is published by Adis. Its print ISSN is 1172-7047 and its online ISSN is 1179-1934.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
CNS Drugs has an h-index of 164 and a 2-year mean of 7.29 citations per paper (OpenAlex). Its Scopus CiteScore is 13.7, quartile Q1. On 2-year citations it ranks #18 of 570 Scopus journals in Psychiatry and Mental Health.
CNS Drugs published 110 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2025–2026), authors are most often from United States (24.8%), Italy (8.8%) and China (7.5%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.